Jeff Yass’s Processa Pharmaceuticals PCSA Stock Holding History

Jeff Yass’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-56	Closed	-$14K	–	12714
2023 Q2	$14K	Buy	+56	New	+$16.5K	﹤0.01%	11710

Other funds holding PCSA

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.62B AUM 36.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Jeff Yass's PCSA Position: Q3 2023 in Review

Jeff Yass sold out of Processa Pharmaceuticals (PCSA) in Q3 2023, closing a stake of 56 shares — an estimated $14K sold.

Jeff Yass first reported a position in PCSA in Q2 2023 and held it in 1 quarter. The position peaked at $14K in Q2 2023. 18 funds tracked by Wall St. Rank hold PCSA as of Q3 2023.

Jeff Yass reported no remaining Processa Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Jeff Yass sold 56 Processa Pharmaceuticals shares in Q3 2023, an estimated $14K.
Jeff Yass first reported a position in Processa Pharmaceuticals in Q2 2023 and held it in 1 quarter.
Jeff Yass's Processa Pharmaceuticals position peaked at $14K in Q2 2023.
18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.